InSphero has reported that organ-on-a-chip solutions can be harnessed to advance diabetes drug discovery.

Horizon’s CHOSOURCE platform is to be combined with Rentschler Biopharma’s novel in-house cell line development process to provide speed, stability and high yield of difficult-to-express proteins.

Moderna, Inc. announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

The UK Government has announced £65.5 million of new funding for the vaccine being developed at the University of Oxford as coronavirus vaccine trials accelerate.

AMSBIO reports on the positive customer feedback received for their One-Step Luciferase Assay kit recently introduced for quantitation of firefly luciferase activity in mammalian cell culture.

Porvair Sciences has reported how its Chromatrap® ChIP kits can provide a solution for antibodies suppliers looking to validate the performance of the antibodies they produce for chromatin immunoprecipitation assay kits.

Avacta has announced that several Affimer reagents have been shown to block the interaction between the SARS-CoV-2 virus’ spike protein and ACE2.

VAXIMM has announced that the safety run-in results from the trial are being presented as an oral presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Meeting.

CEPI to provide up to an additional US$384 million funding for phase 1 and 2 clinical trials and large-scale manufacture of Novavax’ NVX-CoV2373 vaccine candidate, taking total investment in NVX-COV2373 to US $388 million.

The project aims to develop an arsenal of ultrafast new antiviral drug discovery, development and mass-manufacturing tools that will allow a rapid response to prevent future pandemics.